Bahrain becomes 1st nation to grant J&J shot emergency use
Bahrain has become the first nation to authorize Johnson & Johnson’s single-dose vaccine for emergency use
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Bahrain became the first nation to authorize Johnson & Johnson’s new single-dose coronavirus vaccine for emergency use on Thursday, the government announced, just a day after U.S. regulators concluded the shot offers strong protection against severe COVID-19.
The island kingdom off the coast of Saudi Arabia said it would dole out J&J’s shot to the most vulnerable people, including older adults and those with chronic conditions, without specifying when. It was also unclear when doses would be delivered to the country which already offers vaccines by state-backed Chinese firm Sinopharm, Pfizer-BioNtech and Oxford-AstraZeneca, as well as Russia’s Sputnik V to its roughly 2 million residents.
The move makes Bahrain’s health regulatory authority the first in the world to authorize the J&J vaccine for general use. In addition to the U.S., European regulators and the World Health Organization also are considering J&J’s vaccine. Worldwide, the company aims to produce around a billion doses by the end of the year.
Meriam Adhbi al-Jalahma, chief of Bahrain's regulatory body, said authorities had conducted “an in-depth study” on "all documents submitted by the company, which included the results of the clinical trials."
The vaccine “provides a great protection against serious infection with COVID-19,” the statement added.
In an unusual move, South Africa started administering the J&J vaccine to health workers while it was still in testing. The country, where a virus variant is driving a new wave of infections, switched to J&J from AstraZeneca after a small study suggested it was poor at preventing mild to moderate COVID-19 caused by the more contagious variant.
The long-anticipated J&J shot promises to offer the U.S. a third vaccine option and help speed vaccinations by requiring just one dose instead of two. Food and Drug Administration scientists confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19, and about 85% effective against the most serious illness. The agency also said J&J’s shot is safe.
The tiny state of Bahrain has logged 119,858 coronavirus infections and 437 deaths. It boasts among the world's fastest vaccination rates, with nearly 17% of the population having received at least one dose.